aod9604 igf 1 levels AOD 9604 (5mg) - LGI

A higher percentage of participants in the pramlintide groups achieved a weight loss of at least 10% at the 12-month mark compared to the placebo group (40% and 43% vs

The reduction in visceral fat was sustained over the study period, but the fat tended to return to baseline levels upon discontinuation of the therapy, indicating the need for ongoing treatment to maintain these benefits

Voon V, Fernagut P-O, Wickens J, Baunez C, Rodriguez M, Pavon N, et al

AOD-9604 primarily targets fat loss by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage)

5-Amino-1MQ (15mg) is a small-molecule NNMT inhibitor designed to increase NAD+ availability, enhance energy expenditure, and reduce fat cell size